Naman Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 19 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 7.01 Cr
- Satisfied Charges ₹ 8.53 Cr
- Revenue Growth 1000.00%
- Profit Growth 57.43%
- Ebitda 84.79%
- Net Worth -6.30%
- Total Assets -2.52%
About Naman Pharma
Naman Pharma Private Limited (NPPL) is a Private Limited Indian Non-Government Company incorporated in India on 24 November 2005 and has a history of 19 years and two months. Its registered office is in Delhi, India.
The Company is engaged in the Financial Services Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹7.01 Cr. The company has closed loans amounting to ₹8.53 Cr, as per Ministry of Corporate Affairs (MCA) records.
Anjesh Teotia and Satish Kumar serve as directors at the Company.
Company Details
-
Location
Delhi, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U45201DL2005PTC142940
-
Company No.
142940
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
24 Nov 2005
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Naman Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anjesh Teotia
|
Director | 20-Apr-2013 | Current |
|
Satish Kumar
|
Director | 20-Apr-2013 | Current |
Financial Performance of Naman Pharma.
Naman Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 1000% increase. The company also saw a substantial improvement in profitability, with a 57.43% increase in profit. The company's net worth dipped by a decrease of 6.3%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Naman Pharma?
In 2023, Naman Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Kraftstreet Fashion India Private LimitedSatish Kumar is a mutual person
Charges (Loans)
₹70.12 M
₹85.34 M
Charges Breakdown by Lending Institutions
- Others : 7.01 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 29 Aug 2024 | Others | ₹1.80 Cr | Open |
| 02 Feb 2023 | Others | ₹1.43 Cr | Open |
| 24 Jun 2021 | Others | ₹3.78 Cr | Open |
| 10 Oct 2020 | Others | ₹3.69 M | Satisfied |
| 06 Aug 2020 | Others | ₹3.00 Cr | Satisfied |
How Many Employees Work at Naman Pharma?
Unlock and access historical data on people associated with Naman Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Naman Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Naman Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
